Teva CEO Erez Vigodman Steps Down Effective Immediately

Teva has faced numerous recent hurdles, including successful patent challenges to its most important branded product, the multiple sclerosis treatment Copaxone, and a U.S. investigation into generic drug price fixing.

Reuters
Send in e-mailSend in e-mail
Erez Vigodman
Erez VigodmanCredit: Reuven Kapuscinski

Comments